Sensus Healthcare (SRTS) Receiving Somewhat Positive Media Coverage, Analysis Finds

Press coverage about Sensus Healthcare (NASDAQ:SRTS) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sensus Healthcare earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.5695184036668 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

A number of equities analysts have recently commented on SRTS shares. began coverage on shares of Sensus Healthcare in a research report on Friday, July 6th. They issued a “buy” rating and a $12.25 price objective for the company. Roth Capital began coverage on shares of Sensus Healthcare in a research report on Wednesday, August 1st. They set a “buy” rating and a $12.50 target price for the company. Finally, HC Wainwright began coverage on shares of Sensus Healthcare in a research report on Monday, August 27th. They set a “buy” rating and a $14.00 target price for the company. Five investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $11.94.

SRTS stock opened at $6.81 on Friday. Sensus Healthcare has a one year low of $4.31 and a one year high of $8.88. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.49 and a current ratio of 3.80.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, August 2nd. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Sensus Healthcare had a negative return on equity of 26.74% and a negative net margin of 13.07%. The business had revenue of $6.06 million for the quarter, compared to analysts’ expectations of $6.36 million. research analysts forecast that Sensus Healthcare will post -0.19 earnings per share for the current fiscal year.

In other Sensus Healthcare news, insider Joseph C. Sardano sold 6,170 shares of the business’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $7.50, for a total transaction of $46,275.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CTO Kalman Fishman sold 5,626 shares of the business’s stock in a transaction on Monday, June 18th. The shares were sold at an average price of $7.52, for a total transaction of $42,307.52. Following the transaction, the chief technology officer now directly owns 955,023 shares in the company, valued at $7,181,772.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,569 shares of company stock worth $500,638. 41.10% of the stock is owned by insiders.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Article: Investing in Dividend Stocks

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply